Dupixent® (dupilumab) – New indication
May 20, 2022 - Regeneron and Sanofi announced the FDA approval of Dupixent (dupilumab), for the treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE).
Download PDF
